More than 150 Companies Adopt Veeva Vault RIM Applications to Streamline Regulatory Processes

Leading organizations are choosing Vault RIM for a single
authoritative source of content and data
to improve regulatory
business operations and compliance

BETHESDA, Md.–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;#RIMlt;/agt;–DIA Regulatory Submissions, Information, and Document Management
(RSIDM) Forum–
(NYSE:VEEV) today announced increasing numbers of life
sciences companies are adopting applications in Veeva
Vault RIM
, the first unified suite of RIM applications on one cloud
platform, to modernize their regulatory processes and systems. More than
150 companies are implementing Vault RIM applications, including four of
the top 10 largest global pharmaceutical companies, to streamline
submission development and provide greater visibility across end-to-end

Vault RIM brings together regulatory content and data on a single
platform so teams have one authoritative source for submission
documents, published dossiers, health authority interactions, and
product registrations. With Vault RIM, life sciences companies can
eliminate the need for multiple systems and manual tracking that slow
execution and increase compliance risk.

The latest addition to the Vault RIM suite of applications, Veeva
Vault Submissions Publishing
, is a new approach that brings together
publishing activities with document planning, authoring, and approval in
a single system to streamline the entire submission development process.
This enables customers to significantly speed regulatory submission
preparation and delivery. Melinta Therapeutics, for example, cut its
submission development time in half and published 100 submissions within
the first two months of using Vault Submissions Publishing.

Vault Submissions Publishing enables a continuous publishing process to
finish publishing steps sooner so validation issues are identified and
fixed faster for greater efficiency and improved compliance. Continuous
publishing eliminates the manual movement of documents between multiple
systems and reduces the number of document transfers to one – when the
dossier is transmitted directly to the health authority.

“With a continuous publishing model, regulatory teams can identify any
errors and address broken links to source data as the submission is
being built so teams don’t have to go through the lengthy republishing
process over and over,” said Shelly Plapp, director of regulatory
operations at Melinta. “By the time you are ready to publish, the
submission is already quality checked and correct.”

“Veeva innovation is transforming RIM globally across the life sciences
industry,” said John Lawrie, vice president, Veeva Vault RIM. “Melinta
is a great example of how companies can benefit from a single unified
system that streamlines regulatory activities to speed submissions.”

Veeva Vault RIM Suite includes Vault
, Vault
, Vault
Submissions Publishing
, and Vault
Submissions Archive
. Vault RIM is part of Veeva
Development Cloud
, a unified suite of applications for clinical,
regulatory, and quality to help organizations drive end-to-end business
processes across R&D and manufacturing.

Join Veeva and Melinta at the DIA
on Feb. 12, from 1:20 p.m. – 1:35 p.m., in the Solution
Showcase Theater, to learn more about how Melinta accelerated end-to-end
submission development.

For more on continuous publishing, read the article, “How
Continuous Publishing Speeds Regulatory Submissions
,” in DIA
Global Forum

Additional Information

For more on Veeva Vault RIM Suite, visit:

Connect with Veeva on LinkedIn:

Follow @veevasystems on Twitter:

Like Veeva on Facebook:

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 675 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices throughout
North America, Europe, Asia, and Latin America. For more information,

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended October 31, 2018. This is available on the
company’s website at
under the Investors section and on the SEC’s website at
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to


Roger Villareal
Veeva Systems

Lisa Barbadora
Veeva Systems

error: Content is protected !!